Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1009020220200030581
Clinical Psychopharmacology and Neuroscience
2022 Volume.20 No. 3 p.581 ~ p.583
Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report
Ryou Jae-Hyun

Han Doug-Hyun
Lee Ree-Ree
Kim Sun-Mi
Abstract
This case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. This report has shown that the [18F] N ?(3?Fluoropropyl)?2¥â?carbon ethoxy?3¥â?(4?iodophenyl) nortropane positron emission tomography findings of the patient revealed that the dopamine hyperactivity in the basal ganglia at baseline was normalized after aripiprazole treatment due to its balancing effect as a dopamine partial agonist.
KEYWORD
Aripiprazole, Streptococcal infection, Dyskinesia, Basal ganglia, Dopamine
FullTexts / Linksout information
 
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI) KoreaMed